{"url_path":"/sec/mreo/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-343519-index.html","accession_number":"0001193125-26-343519","cik":"0001719714","ticker":"MREO","issuer_name":"Mereo BioPharma Group plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-343519-index.html","primary_entity_key":"0001719714","primary_entity_name":"Mereo BioPharma Group plc"},"word_count":141,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, Mereo BioPharma Group plc announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent corporate developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing."}